Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed
26.10.2026 12:28:00 EET | Business Wire | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/
Oral-B iO
Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia.
"Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry and is Senior Scientific Relations Manager for Oral-B in the UK. "The worst thing you can do is nothing. Gingivitis can be reversed with proper oral hygiene, but periodontitis can only be managed. If your gums don't improve within two weeks, see your dentist or dental hygienist."
Why do my gums bleed when I brush or floss?
Bleeding when brushing or flossing often indicates gingivitis, an inflammation of the gum tissue typically caused by a buildup of plaque. Bacteria in plaque irritate the gums, making them red, swollen and prone to bleeding.
However, gum disease is not the only possible cause. Bleeding gums can also be associated with aggressive brushing (brushing too hard or with stiff bristles can also damage delicate gum tissue), hormonal changes, vitamin deficiencies, certain medications, diabetes, smoking, ill-fitting dentures and blood-clotting disorders.
Should I stop flossing if my gums bleed?
No. Bleeding when flossing is often a sign of inflammation, and continuing to floss gently can help reduce it and improve gum health. Avoiding flossing can lead to more plaque buildup, making the problem worse.
What's the difference between gingivitis and periodontitis?
Gingivitis | Periodontitis | |
Stage | First stage of gum disease | More severe, advanced stage of gum disease |
Reversible? | Yes, with proper oral hygiene | No, it can only be managed and treated |
Signs | Swollen, red or bleeding gums | Bleeding, receding gums, loose teeth |
When should I see a dentist?
Occasional gum bleeding is not uncommon, but frequent, persistent or heavy bleeding should be taken seriously. If the bleeding persists, worsens or does not improve, consult a dentist or dental hygienist. They can assess your oral health, examine your gums, identify underlying issues that may be causing the bleeding, and recommend appropriate treatment options.
Is an electric toothbrush better for gum health than a manual one?
Yes. Electric toothbrushing has been scientifically proven to make a noticeable difference in your oral health, compared to using a manual toothbrush. Oral-B iO helps you avoid new tooth and gum issues, and if you have existing gingivitis, it can resolve it quicker than a manual toothbrush. Pair Oral-B toothpaste with an Oral-B iO electric toothbrush to help stop bleeding and reverse signs of early gum disease. Its gentle micro-vibrations and smart pressure sensor help you deliver an effective clean while protecting your gums.
When you brush with Oral-B iO, you can protect your gums and help prevent future gum recession. A study found that for subjects susceptible to gingival recession, an electric toothbrush was a safe option over 36 months.¹ Pair it with an advanced brush head, such as the Oral-B iO Gentle Care, designed to deliver an effective yet gentle clean along the gumline. This superior cleaning performance is reflected in multiple independent clinical studies, which show that Oral-B iO provides 100% more plaque removal and 6x more plaque removal along the gumline than a manual toothbrush, together with 14.5x higher odds of moving from non-healthy to healthy gums compared to regular manual toothbrush users.
Can toothpaste help treat early gum disease, or only prevent it?
Both. Toothpastes containing stannous fluoride, such as Oral-B Pro-Expert, are specially formulated to target and neutralise the harmful plaque bacteria that build up around the gumline, helping to treat and prevent gingivitis. Complete the routine with daily flossing and Oral-B Mouthwash, clinically proven to provide 24-hour protection against plaque and gingivitis with twice-daily use.
1. | Sutor, S., et al. (2025). Effect of a powered and a manual toothbrush in subjects susceptible to gingival recession: a 36-month randomized controlled clinical study. International Journal of Dental Hygiene, 23(1), 26–36. |
About Oral-B
Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261022835650/en/
Contacts
Media Contact: For more information please contact
ORALCARERBU_MSL_TEAM_GBR@pgone.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom